Who founded Autobahn Therapeutics, Inc.?

Autobahn Therapeutics, Inc. was founded by Kevin Finney in 2017.

Who are Autobahn Therapeutics, Inc.'s investors?

Autobahn Therapeutics, Inc.'s investors include ARCH Venture Partners, Canaan Partners, Monograph Capital Partners, Pfizer Venture Investments, Samsara BioCapital, Newpath Partners.

How much funding has Autobahn Therapeutics, Inc. raised?

Autobahn Therapeutics, Inc. has disclosed $100.8M raised across 1 round.

Where is Autobahn Therapeutics, Inc. headquartered?

Autobahn Therapeutics, Inc. is headquartered in San Diego, US.

Autobahn Therapeutics, Inc.

San Diego, US · Founded 2017 · Delaware corporation · 6 known investors

autobahntx.com ↗

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders. The company targets both rare and prevalent brain diseases, using biomarker-driven development strategies to demonstrate on-target activity early in clinical trials.

BiotechDeep TechMedical Devices

Founders & leadership

Autobahn Therapeutics, Inc. was founded in 2017 by Kevin Finney.

Kevin FinneyChairman, President and CEO

John BorkholderExecutive

Board

Kristina Burow inBoard directorManaging Director at ARCH Venture Partners

Thomas CahillBoard directorManaging Partner at Newpath Partners

Timothy AndersonBoard director

Philip J DeSouzaBoard director

Bonnie van WilgenburgBoard directorPrincipal at Monograph Capital Partners

Uwe SchoenbeckBoard directorInvestor at Canaan Partners

Benjamin CravattBoard director

Scott GiacobelloBoard director

Investors · 6

ARCH Venture PartnersChicago · $50K – $250Mvia Kristina Burow · board

Canaan PartnersStamford · $500K – $20M

Monograph Capital PartnersLondon

Pfizer Venture Investments$5M – $20M

Samsara BioCapitalPalo Alto

Newpath Partnersreported · 2 sourcesBoston · $50K – $10M

Reported raises · per SEC filings

Form D private placements

$100.8M disclosed across 1 round · 2024

▶$100.8MraisedAug 2024 · 22 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Uwe SchoenbeckDirector
John BorkholderExecutive Officer
Kristina BurowDirector
Thomas CahillDirector
Timothy AndersonDirector
Philip J DeSouzaDirector
Benjamin CravattDirector
Scott GiacobelloDirector
Kevin FinneyExecutive Officer, Director
Bonnie van WilgenburgDirector

Offering amount: $120M
Amount sold: $100.8M
First sale: Jun 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Doximity8 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.

Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Autobahn Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Autobahn Therapeutics to Participate in Multiple Upcoming June 2026 Investor Conferences - BioSpacebiospace.com · May 2026

Autobahn Therapeutics Secures $200M in Series C Funding for Revolutionary CNS Drug Developmentleadsontrees.com · Jul 2024

Autobahn Therapeutics, Inc. announced that it has received $100.825289 million in funding from a group of investors | MarketScreener Indiain.marketscreener.com · Jul 2024

Frequently asked questions

What does Autobahn Therapeutics, Inc. do?: Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders. The company targets both rare and prevalent brain diseases, using biomarker-driven development strategies to demonstrate on-target activity early in clinical trials.
Who founded Autobahn Therapeutics, Inc.?: Autobahn Therapeutics, Inc. was founded by Kevin Finney in 2017.
Who are Autobahn Therapeutics, Inc.'s investors?: Autobahn Therapeutics, Inc.'s investors include ARCH Venture Partners, Canaan Partners, Monograph Capital Partners, Pfizer Venture Investments, Samsara BioCapital, Newpath Partners.
How much funding has Autobahn Therapeutics, Inc. raised?: Autobahn Therapeutics, Inc. has disclosed $100.8M raised across 1 round.
Where is Autobahn Therapeutics, Inc. headquartered?: Autobahn Therapeutics, Inc. is headquartered in San Diego, US.